Xspray Pharma AB (publ) announced that the company has appointed Thomas Walz to the newly established position Chief Medical Officer (CMO). Thomas joins Xspray Pharma from a senior role at GSK and will take up the
new position in September 2022. Thomas was previously the Head of Department of Oncology at Karolinska University Hospital and has extensive experience in from the pharmaceutical industry. He most recently joins from the position as the Nordic Medical Director of Oncology at GSK. Thomas is a specialist in oncology and associate professor at Linköping University and has an MBA from the Stockholm School of Economics. The new role will include establishing Xspray Pharma's global Medical Affairs function, preparing the launch of the first products and the overall responsibility for clinical development plans. Thomas joins on September 1st and will be part of Xspray Pharma's management team.